Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50. A De Giglio, L Zullo, A Di Federico, M Cani, M Aldea, D Soldato, F G Dall'Olio, F Mantuano, F Sperandi, V Favorito, A Sadowska, L E L Hendriks, T Gorria, L Mezquita, F Tabbò, S Novello, F Gelsomino, B Besse, A Ardizzoni

https://read.qxmd.com/read/41252810/immunotherapy-beyond-progression-combined-with-platinum-based-chemotherapy-after-primary-resistance-to-first-line-immunotherapy-in-patients-with-advanced-nsclc-and-pd-l1-50?uac=148436CN&ecd=wnl_readmost_251226&sso=true&redirected=slug Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50. Primary resistance to immune checkpoint inhibitors (ICIs) remains a major challenge in patients with advanced non-small-cell lung cancer (NSCLC) and programmed .. Nov 17, 2025: ESMO Open